Xtant Medical Holdings, Inc.
AMEX:XTNTMedical - Devices
-$0.00 today
- Market cap
- $50.37M
- Beta
- -0.17
- P/E (TTM)
- 33.4
- EPS (TTM)
- $0.01
Volume 0.16M
Average 0.16M
XTNT EBITDA Margin
EBITDA as a percentage of revenue.
Xtant Medical Holdings, Inc.AMEX: XTNT
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin narrows to -9.2%
EBITDA Margin was -9.2% in Q1 FY2026, down 15.8 pp from a year earlier. On a trailing-twelve-month basis it was 9.7%, up 12.3 pp year over year. Over 3 fiscal years it widened by 21.2 pp.
Context
- EBITDA Margin widened in 2 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 3 analysts of 4.6% for the fiscal year ending Dec 2026, down from 11.9% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -9.2%-22.0 pp QoQ
- Last fiscal yearDec 2025
- 11.9%+18.6 pp YoY
- LTMMar 2026
- 9.7%+12.3 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -15.8 pp | -23.9 pp | -8.2 pp |
| 1 year | +18.6 pp | -7.3 pp | -25.9 pp |
| 3 years | +21.2 pp | -2.8 pp | -24.0 pp |
| 5 years | — | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 11.9%
- Year-over-year change
- +18.6pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 11.9% | +18.6pp |
| FY2024 | 2024-12-31 | -6.7% | -12.3pp |
| FY2023 | 2023-12-31 | 5.6% | +14.9pp |
| FY2022 | 2022-12-31 | -9.4% | -4.8pp |
| FY2021 | 2021-12-31 | -4.5% | — |
EBITDA Margin vs competitors
How XTNT compares with its peers on the latest reported figures
- XTNT's LTM Mar 2026 EBITDA Margin of 9.7% is the 2nd highest of the 6 companies compared; the peer median is -52.1%.
- Its year-over-year change of +12.3 pp is the 4th highest of 6, against a peer median of +18.1 pp.
- Over three fiscal years its change of +21.2 pp compares with a peer median of +40.8 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 15.1% | -3.2 pp | -10.6 pp | |
| LTM Mar 2026 | 9.7% | +12.3 pp | +21.2 pp | |
| LTM Mar 2026 | -4.4% | +24.0 pp | +40.8 pp | |
| LTM Mar 2026 | -52.1% | +18.1 pp | +20.4 pp | |
| LTM Mar 2026 | -131.2% | +8.9 pp | +214.5 pp | |
| LTM Mar 2026 | -859.3% | +600.4 pp | +13170.1 pp | |
| FY2025 | — | — | — | |
EXOZeXoZymes, Inc. | FY2025 | — | — | — |
| Peer median (excluding XTNT) | -52.1% | +18.1 pp | +40.8 pp | |
Competitors are the stored peer set for XTNT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 55.26M | 57.97M | 91.3M | 117.27M | 133.93M |
| Cost of Revenue | 22.77M | 25.83M | 35.84M | 49.05M | 49.65M |
| Gross Profit | 32.49M | 32.14M | 55.47M | 68.22M | 84.27M |
| Gross Margin | 58.8% | 55.4% | 60.8% | 58.2% | 62.9% |
| Research & Development | 870K | 915K | 1.34M | 2.39M | 2.1M |
| Selling, General & Admin | 35.47M | 37.98M | 64.29M | 77.91M | 74.89M |
| Operating Expenses | 36.34M | 38.89M | 65.63M | 80.29M | 76.99M |
| Depreciation & Amortization | 1.34M | 1.3M | 3.17M | 4.22M | 5.22M |
| EBITDA | (2.51M) | (5.43M) | 5.08M | (7.88M) | 15.9M |
| EBITDA Margin | -4.5% | -9.4% | 5.6% | -6.7% | 11.9% |
| Operating Income | (3.85M) | (6.76M) | (10.16M) | (12.07M) | 7.28M |
| Operating Margin | -7.0% | -11.7% | -11.1% | -10.3% | 5.4% |
| Interest Income | 0 | 31K | 149K | 0 | 94K |
| Interest Expense | 995K | 1.69M | 2.94M | 4.16M | 3.67M |
| Other Income / Expenses | (995K) | (1.66M) | 9.12M | (4.19M) | (283K) |
| Income Before Tax | (4.85M) | (8.42M) | (1.04M) | (16.26M) | 7M |
| Pre-Tax Margin | -8.8% | -14.5% | -1.1% | -13.9% | 5.2% |
| Income Tax Expense | 0 | 69K | (1.7M) | 187K | 2.03M |
| Net Income | (4.85M) | (8.49M) | 660K | (16.45M) | 4.97M |
| Net Margin | -8.8% | -14.6% | 0.7% | -14.0% | 3.7% |
| EPS (Basic) | (0.06) | (0.09) | 0.01 | (0.12) | 0.04 |
| EPS (Diluted) | (0.06) | (0.09) | 0.01 | (0.12) | 0.03 |
| Weighted Avg Shares | 85.46M | 94.09M | 119.09M | 133.67M | 139.53M |
| Weighted Avg Shares (Diluted) | 85.46M | 94.09M | 126.79M | 133.67M | 150.04M |
Xtant Medical Holdings, Inc.
AMEX:XTNT
Intrinsic Alpha fair value
Locked
Current Price
$0.36
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.